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The liver is the site of synthesis of many proteins involved
in hemostasis, including procoagulant and anticoagulant
proteins, profibrinolytic and antifibrinolytic proteins, and
thrombopoietin. Consequently, patients with liver disease
acquire complex changes within their hemostatic system
[1]. Historically, these changes were thought to result in a
bleeding diathesis. Although bleeding complications are
common in patients with chronic liver disease, the most
common bleeding complication, variceal bleeding, is a
consequence of portal hypertension, rather than hemo-
static failure. Notably, the severity and outcome of vari-
ceal bleeding were not different between patients with
cirrhosis who did or did not use anticoagulant drugs at
the time of the bleed, confirming that variceal bleeding is
unrelated to hemostatic failure [2]. Severe bleeding was
previously common during large invasive procedures such
as liver transplant surgery. However, improvements in
perioperative management have led to a substantial
decline in bleeding severity during the transplant proce-
dure. Now, a substantial proportion of patients undergo
transplant surgery without the requirement for any peri-
operative blood product transfusion [3]. These clinical
observations, combined with laboratory analyses of glo-
bal hemostatic capacity, have led to the concept of rebal-
anced hemostasis [4]. Patients with liver disease appear to
have a reset in their hemostatic balance, owing to simul-
taneous declines in procoagulant and anticoagulant dri-
vers. This new hemostatic balance, however, is much
more fragile than the balance in healthy individuals, and
may abruptly tip to either a hypocoagulable or hyperco-
agulable phenotype.
Although, historically, bleeding was a major concern in
patients with liver disease, the focus has now shifted to
thrombotic complications. Recent studies, including meta-
analyses, have demonstrated that chronic liver diseases
constitute a risk factor for venous thrombosis [5]. How-
ever, the prevention and treatment of venous thrombosis
are complex, as it is not established how to best anticoag-
ulate a patient with a profoundly altered hemostatic sys-
tem at baseline [6]. Another frequent thrombotic
complication in patients with advanced chronic liver dis-
ease is portal vein thrombosis (PVT). PVT in the patient
with advanced cirrhosis is often discovered incidentally
during imaging. There is debate about whether PVT is
simply a reflection of the severity of liver disease [7], or
whether PVT drives progression of disease [8]. Conse-
quently, it is unclear whether treatment of asymptomatic
PVT is required. Notably, some of the asymptomatic
thrombi resolve spontaneously [7], and prolonged antico-
agulant treatment leads to recanalization in only a propor-
tion of patients [9]. A single small randomized controlled
trial has demonstrated that prophylactic low molecular
weight heparin (LMWH) safely and effectively prevents
the development of PVT in a very select group of patients
with cirrhosis [10]. Interestingly, LMWH also decreased
the rate of decompensation and death, indicating that
anticoagulant therapy might delay disease progression,
and that prevention rather than (considering) treatment of
PVT should be the focus of treatment paradigms.
The concept of rebalanced hemostasis states that all
components of hemostasis are in a new balance, with
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thrombocytopenia balanced by elevated plasma levels of
von Willebrand factor, decreased plasma levels of proco-
agulants balanced by decreased levels of anticoagulants,
and decreased plasma levels of antifibrinolytics balanced
by decreased plasma levels of plasminogen (summarized
in [1]). However, upon careful inspection, the hemostatic
system of a patient with advanced chronic liver disease
(i.e. cirrhosis) has clear hypercoagulable features. Such
prothrombotic features include an imbalance in the von
Willebrand factor–ADAMTS-13 axis, platelet hyperfunc-
tion, elevated levels of intravascular tissue factor, and
decreased permeability of the fibrin clot (summarized in
[11]). Furthermore, thrombin-generating capacity is
elevated when it is tested with thrombomodulin-modified
thrombin generation testing.
In 2005, it was first demonstrated that the thrombin-
generating system in patients with cirrhosis is much more
competent than expected on the basis of diagnostic tests
of hemostasis [12]. The prothrombin time and activated
partial thromboplastin time are prolonged in patients
with cirrhosis, suggesting a hypocoagulable state. How-
ever, these diagnostic tests are only sensitive for procoag-
ulant proteins, and are unrelated to hemostatic capacity
in patients with disorders in both procoagulant and anti-
coagulant proteins. Thrombin generation tests, such as
calibrated automated thrombinography, are sensitive for
anticoagulant systems, but a full representation of hemo-
static balance between procoagulant and anticoagulant
proteins is only obtained when the thrombin generation
test is modified to allow for activation of the protein C
system, e.g. by the addition of soluble thrombomodulin
to the test mixture. Although the initial article in 2005
demonstrated similar thrombin-generating capacity
between healthy individuals and patients with cirrhosis in
thrombomodulin-modified thrombin generation tests [12],
subsequent studies by multiple independent laboratories
have actually demonstrated increased thrombin genera-
tion in patients [13–16].
An article by Sinegre et al. in this issue of the Journal
of Thrombosis and Haemostasis addresses the question of
which factors determine enhanced thrombin-generating
capacity in patients with cirrhosis [13]. Previous studies
have demonstrated that regulation of thrombin genera-
tion by the protein C pathway is decreased in patients
with cirrhosis, and that normal to increased thrombin
generation in thrombomodulin-modified thrombin genera-
tion tests relates to resistance to the anticoagulant action
of thrombomodulin [17]. This thrombomodulin resistance
is a result of both decreased plasma levels of protein C
and increased plasma levels of factor VIII [18,19].
Recently, the ratio between the results of thrombin gener-
ation tests performed in the absence and in the presence
of thrombomodulin, or the ratio between FVIII and pro-
tein C levels, have been used to indicate a hypercoagula-
ble status in patients with cirrhosis [17,20]. However, as
these ratios are not necessarily related to overall throm-
bin-generating capacity, it may be more appropriate to
assess the results of the thrombomodulin-modified throm-
bin generation test in determining the hemostatic capacity
of plasma from patients with cirrhosis. Sinegre et al. did
exactly this, and demonstrated increased thrombin gener-
ation in patients with cirrhosis as compared with healthy
controls, with thrombin-generating capacity increasing
with increasing disease severity. The authors addressed
the roles of elevated FVIII and decreased protein C levels
in the hypercoagulable state of patients with cirrhosis by
normalizing plasma levels in individual patient samples.
Protein C levels were normalized by the addition of puri-











































Fig. 1. Effect of normalization of antithrombin (AT) plasma levels
on thrombomodulin-modified thrombin generation in plasma from
patients with cirrhosis. (A) AT plasma levels were measured on an
automated coagulation analyzer (ACL 300 TOP) with reagents and
protocols from the manufacturer (Werfen, Breda, the Netherlands)
in 15 patients with cirrhosis (six related to alcohol abuse, four to
non-alcoholic steatohepatitis, four to viral hepatitis, and one to pri-
mary sclerosing cholangitis, with a median model of end-stage liver
disease score of 10, range 7–18) and 44 healthy controls. Patients
and controls provided informed consent, and the study protocol was
approved by the medical ethical committee of the University Medical
Center Groningen. In the patient samples, AT levels were normalized
by addition of AT concentrate (Shire, Lexington, MA, USA), and
plasma levels of AT were reassessed. (B) Thrombomodulin-modified
thrombin generation assays were performed on citrated platelet-poor
plasma by the use of calibrated automated thrombinography with
reagents and protocols from the manufacturer (Thrombinoscope,
Maastricht, The Netherlands) in healthy controls, patients with cir-
rhosis, and patient samples in which AT levels were normalized.
Horizontal lines indicate medians.
© 2018 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
Thrombosis and Haemostasis.
Thrombin generation in cirrhosis 1129
very elegant approach in which some of the plasma FVIII
was inactivated by an antibody against FVIII, which was
titrated so that residual FVIII activity was close to 100%.
The authors showed that the increased thrombin genera-
tion in patients was only partly normalized when only
protein C or only FVIII was normalized, but full normal-
ization occurred when protein C and FVIII levels were
normalized simultaneously. The authors carefully con-
clude that enhanced thrombin generation in patients with
cirrhosis is explained by opposite changes in plasma levels
of FVIII and protein C. Although high FVIII and low
protein C levels clearly contribute to enhanced thrombin
generation in patients with cirrhosis, this is probably only
part of the story.
Thrombin-generating capacity is the net result of
plasma levels of procoagulant and anticoagulant proteins,
all of which (perhaps except for levels of tissue factor
pathway inhibitor) are altered in patients with cirrhosis.
To demonstrate that high FVIII and low protein C levels
are not the only contributors to enhanced thrombin gen-
eration in patients with cirrhosis, we studied thrombo-
modulin-modified thrombin generation in 15 patients with
cirrhosis and decreased antithrombin plasma levels before
and after normalization of antithrombin levels. As shown
in Fig. 1A, antithrombin levels were substantially
decreased in patients as compared with 44 healthy indi-
viduals, and levels were normalized after in vitro addition
of antithrombin concentrate. Figure 1B shows elevated
thrombin generation in patients as compared with con-
trols, which was fully normalized when antithrombin
plasma levels were normalized. These data are almost
identical to the data in Figure 4 of the Sinegre et al. arti-
cle, and illustrate that enhanced thrombin generation in
cirrhosis is the result of multiple complex changes in the
plasma levels of procoagulant and anticoagulant proteins
that not limited to high FVIII and low protein C levels.
Thus, Sinegre et al. confirm and extend previous find-
ings on the mechanisms underlying enhanced thrombin
generation in plasma from patients with cirrhosis by
showing that not only low protein C levels [18], but also
high FVIII levels contribute to the hypercoagulable state.
However, as the coagulation potential in cirrhosis
depends on the interaction between all procoagulants and
anticoagulants, isolated assessment of FVIII or protein C
levels in these patients yields incomplete information.
Rather, global tests such as thrombomodulin-modified
thrombin generation should be used to estimate the
hemostatic status of these patients.
Notwithstanding the complexity of the mechanisms
underlying the enhanced in vitro thrombin generation in
patients with cirrhosis, the data of Sinegre et al. help us
to better understand the mechanisms underlying this par-
ticular hypercoagulable feature in the hemostatic system
with complex alterations in patients with cirrhosis. Future
studies will have to address whether enhanced thrombin
generation in patients with cirrhosis contributes to the
elevated risk of important clinical outcomes, such as
venous thrombosis and/or PVT, and what steps should be
taken to safely neutralize this hypercoagulable phenotype
in order to avoid these potentially devastating thrombotic
events in this patient population.
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